Absci Corp at Goldman Sachs Healthcare Conference Transcript
I'm Sean McClain, founder and CEO of Absci. We're a generative AI drug creation company.
So when I founded the company 15 years ago, originally we were not focused on AI drug discovery. We were focused on.
How we can scale technology to look at protein-protein interactions. And we were an early adopter of generative AI in 2018, looking at how we can take this protein-protein interaction data with these transformers and really be able to go after hard-to-drug targets and start to engineer biology to be able to go after hard targets like GPCRs, ion channels. And we're at an exciting inflection point now in the history of Avcai where we're actually starting to see the drugs that we've designed with our AI go into the clinic and within the next 24 months, we'll have two Phase II clinical readouts. From ABS-201 for androgenic alopecia as well as endometriosis. I think it's a very differentiated pipeline that we're building out with the prolactin receptor biology.
So when we think about. Drug discovery and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
